论文部分内容阅读
目的研究非小细胞肺癌(NSCLC)患者外周血辅助性T细胞17(Th17)细胞、调节性T细胞(Treg)及其相关细胞因子[白细胞介素-17(IL-17)和转化生长因子-β(TGF-β)]的变化。方法 82例非小细胞肺癌患者,随机分为对照组40例(NSCLC一线化疗方案),试验组42例(化疗联合华蟾素50 m L qd),以本院同期健康体检者29例为正常组。用流式细胞术检测3组治疗前后的外周血Th17、Treg细胞占CD4~+T细胞比例;酶联免疫吸附试验(ELISA)法检测血清中IL-17和TGF-β的水平。结果治疗前NSCLC组(试验组+对照组)Th17细胞占CD4~+T细胞比例为(1.21±0.52)%,低于正常组的(1.92±0.69)%,Treg细胞占CD4~+T细胞比例为(8.04±0.92)%,高于正常组的(2.64±0.78)%(P<0.01);对照组和试验组血清IL-17水平低于正常组,TGF-β水平高于正常组(P<0.01)。治疗后,与对照组比较,试验组的Th17细胞、Treg细胞水平和IL-17水平差异有统计学意义(均P<0.05);治疗后,试验组TGF-β水平低于对照组,但差异无统计学意义(P>0.05)。结论华蟾素可有效改善NSCLC患者免疫功能异常,提高患者免疫力。
Objective To study the expression of Th17, Treg and related cytokines [interleukin-17 (IL-17) and transforming growth factor-β (TGF-β1) in peripheral blood of patients with non-small cell lung cancer β (TGF-β)] changes. Methods 82 patients with non-small cell lung cancer were randomly divided into control group of 40 patients (NSCLC first-line chemotherapy), the experimental group of 42 patients (chemotherapy combined with cinobufotalin 50 m L qd), the same period in our hospital 29 healthy subjects were normal group. The levels of Th17 and Treg cells in CD4 + T cells in peripheral blood of three groups before and after treatment were detected by flow cytometry. The levels of IL-17 and TGF-β in serum were detected by enzyme linked immunosorbent assay (ELISA). Results Th17 cells accounted for (1.21 ± 0.52)% in the NSCLC group (experimental group + control group) before treatment, which was significantly lower than that in the normal group (1.92 ± 0.69)%. The proportion of Treg cells in CD4 ~ + T cells (8.04 ± 0.92)%, higher than that of the normal group (2.64 ± 0.78)% (P <0.01). The levels of serum IL-17 in the control group and the experimental group were lower than those in the normal group <0.01). After treatment, compared with the control group, the levels of Th17 cells, Treg cells and IL-17 in the experimental group were significantly different (all P <0.05); after treatment, the levels of TGF-β in the experimental group were lower than those in the control group No statistical significance (P> 0.05). Conclusion Cinobufacini can effectively improve the abnormal immune function of NSCLC patients and improve the immunity of patients.